Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary δ opioid antagonist activity

Journal of Medicinal Chemistry

Volumn 40, Issue 19, 1997, Pages 3100-3108

  Salvadori, Severe ^a   Balboni, Gianfranco ^a   Guerrini, Remo ^a   Tomatis, Roberto ^a   Bianchi, Clementina ^c   Bryant, Sharon D ^b   Cooper, Peter S ^b   Lazarus, Lawrence H ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c NIEHS ^*

Author keywords

[No Author keywords available]

Indexed keywords

DELTA OPIATE RECEPTOR ANTAGONIST; DRUG CARRIER; MORPHINE;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHIRALITY; GUINEA PIG; METHYLATION; RECEPTOR AFFINITY;

ANIMALS; BINDING, COMPETITIVE; CELL MEMBRANE; DIPEPTIDES; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; ENKEPHALIN, D-PENICILLAMINE (2,5)-; ENKEPHALINS; GUINEA PIGS; ILEUM; INDICATORS AND REAGENTS; ISOQUINOLINES; KINETICS; MALE; METHYLATION; MICE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; NARCOTIC ANTAGONISTS; RADIOLIGAND ASSAY; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VAS DEFERENS;

EID: 0030880687     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9607663     Document Type: Article

References (95)

1. 2, the negative log of the molar concentration necessary to double the concentration of agonist needed to elicit the original response; tBu, tert-butyl; TEA, triethylamine; TFA, trifluoroacetic acid; Tic, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; TLC, thin-layer chromatography; WSC, 1-ethyl-3-(3′-(dimethyl)aminopropyl)carbodiimide hydrochloride; Z, benzyloxycarbonyl.
2. (a) Erspamer, V. The opioid peptides of the amphibian skin. Int. J. Dev. Neurosci. 1992, 10, 3-30.
3. (b) Lazarus, L. H.; Attila, M. The toad, ugly and venomous, wears yet a precious jewel in his skin. Prog. Neurobiol. 1993, 41, 473-507.
4. (a) Lazarus, L. H.; Salvadori, S.; Tomatis, R.; Wilson, W. E. Opioid receptor selectivity reversal in deltorphin tetrapeptide analogues. Biochem. Biophys. Res. Commun. 1991, 178, 110-115.
5. (b) Sagan, S.; Charpentier, S.; Delfour, A.; Amiche, A.; Nicolas, P. The aspartic acid in deltorphin I and dermenkephalin promotes targeting to δ-opioid receptor independently of receptor binding. Biochem. Biophys. Res. Commun. 1992, 187, 1203-1210.
6. (a) Lazarus, L. H.; Salvadori, S.; Santagada, V.; Tomatis, R.; Wilson, W. E. Function of negative charge in the "address domain" of deltorphins. J. Med. Chem. 1991, 34, 1350-1359.
7. (b) Lazarus, L. H.; Salvadori, S.; Attila, M.; Grieco, P.; Bundy, D. M.; Wilson, W. E.; Tomatis, R. Interaction of deltorphin with opioid receptors: Molecular determinants for affinity and selectivity. Peptides 1993, 14, 21-28.
8. (a) Bryant, S. D.; Attila, M.; Salvadori, S.; Guerrini, R.; Lazarus, L. H. Molecular dynamics conformations of deltorphin analogues advocate δ opioid binding site models. Pept. Res. 1994, 7, 175-184.
9. (b) Breveglieri, A.; Guerrini, R.; Salvadori, S.; Bianchi, C.; Bryant, S. D.; Attila, M.; Lazarus, L. H. Design and synthesis of 1-aminocycloalkane-1-carboxylic acid-substituted deltorphin analogues: unique δ and μ opioid activity in modified peptides. J. Med. Chem. 1996, 39, 733-780.
10. Sagan, S.; Amiche, M.; Delfour, A.; Mor, A.; Camus, A.; Nicolas, P. Differential contribution of C-terminal regions of dermorphin and dermenkephalin to opioid-sites selection and binding potency. Biochem. Biophys. Res. Commun. 1989, 163, 726-732.
11. Tancredi, T.; Salvadori, S.; Amodeo, P.; Picone, D.; Lazarus, L. H.; Bryant, S. D.; Guerrini, R.; Marzola, G.; Temussi, P. A. Conversion of enkephalin and dermorphin into δ-selective opioid antagonists by single-residue substitution. Eur. J. Biochem. 1994, 224, 221-247.
12. Salvadori, S.; Attila, M.; Balboni, G.; Bianchi, C.; Bryant, S. D.; Crescenzi, O.; Guerrini, R.; Picone, D.; Tancredi, T.; Temussi, P. A.; Lazarus, L. H. δ Opioidmimetic antagonists: Prototypes for designing a new generation of ultraselective opioid peptides. Mol. Med. 1995, 1, 678-689.
13. (a) Temussi, P. A.; Salvadori, S.; Amodeo, P.; Bianchi, C.; Guerrini, R.; Tomatis, R.; Lazarus, L. H.; Tancredi, T. Selective opioid dipeptides. Biochem. Biophys. Res. Commun. 1994, 198, 933-939.
14. (b) Mosberg, H. I.; Omnass, J. R.; Sobczyk-Kojiro, K.; Dua, R.; Ho, J. C.; Ma, W.; Bush, P.; Mousigan, C.; Lomize, A. Pharmacophore elements of the TIPP class of delta opioid receptor antagonists. Lett. Pept. Sci. 1994, 1, 69-72.
15. (a) Schiller, P. W.; Nguyen, T. M.-D.; Weltrowska, G.; Wilkes, B. C.; Marsden, B. J.; Lemieux, C.; Chung, N. N. Differential stereochemical requirements of μ vs. δ opioid receptors for ligand binding and signal transduction: Development of a class of potent and highly δ-selective peptide antagonists. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 11871-11875.
16. (b) Schiller, P. W.; Weltrowska, G.; Nguyen, T. M.-D.; Wilkes, B. C.; Chung, N. N.; Lemieux, C. TIPP[Ψ]: A highly potent and stable pseudopeptide δ opioid receptor antagonist with extraordinary δ selectivity. J. Med. Chem. 1993, 36, 3182-3187.
17. Schiller, P. W.; Nguyen, T. M.-D.; Weltrowska, G.; Wilkes, B. C.; Marsden, B. J.; Schmidt, R.; Lemieux, C.; Chung, N. N. TIPP opioid peptides: Development of extraordinarily potent and selective δ antagonists and observation of astonishing structure-intrinsic activity relationships. In Peptides: Chemistry and Biology; Hodges, R. S.; Smith, J. A., Eds.; ESCOM: Leiden, 1994, 483-486.
18. Roques, B. P.; Gacel, G.; Fournie-Zaluski, M.-C.; Senault, B.; Lecomte, J.-M. Demonstration of the crucial role of the phenylalanine moiety in enkephalin analogues for differential recognition of the μ- and δ-receptors. Eur. J. Pharmacol. 1979, 60, 109-110.
19. Dygos, J. H.; Yonan, E. E.; Scaros, M. G.; Goodmonson, O. J.; Getman, D. P.; Periana, R. A.; Beck, G. R. A convenient asymmetric synthesis of the unnatural amino acid 2,6-dimethyl-L-tyrosine. Synthesis 1992, 8, 741-743.
20. (a) Chandrakumar, N. S.; Yonan, P. K.; Stapelfeld, A.; Savage, M.; Rorbacher, E.; Conteras, P. C.; Hammond, D. Preparation and opioid activity of analogues of the analgesic dipeptide 2,6-dimethyl-L-tyrosyl-N-(3-phenylpropyl)-D-alaninamide. J. Med. Chem. 1992, 35, 223-233.
21. 5]enkephalin. J. Med. Chem. 1992, 35, 684-687.
22. (c) Pitzele, B. S.; Hamilton, R. W.; Kudla, R. D.; Tsymbalov, S.; Stapelfeld, A.; Savage, M. A.; Clare, M.; Hammond, D. L.; Hansen, D. W., Jr. Enkephalin analogues as systemically active antinociceptive agents: O- and N-alkylated derivatives of the dipeptide amide L-2,6-dimethyltyrosyl-N-(3-phenylpropyl)-D-alaninamide. J. Med. Chem. 1994, 37, 888-896.
23. 1]deltorphin B. Eur. J. Pharmacol. 1996, 302, 37-42.
24. (a) Abdelhamid, E. E.; Sultana, M.; Portoghese, P. S.; Takemori, A. E. Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J. Pharmacol. Exp. Ther. 1991, 258, 299-303,
25. (b) Horan, P.; Tallarida, R. J.; Haaseth, R. C.; Matsunaga, T. O.; Hruby, V. J.; Porreca, F. Antinociceptive interactions of opioid delta receptor agonists with morphine in mice: supra- and sub-additivity. Life Science 1992, 50, 1535-1541.
26. (c) Fundytus, M. E.; Schiller, P. W.; Shapiro, M.; Weltrowska, G.; Coderre, T. J. Attenuation of morphine tolerance and dependence with the highly selective δ-opioid receptor antagonist TIPP[π]. Eur. J. Pharmacol. 1995, 286, 105-108.
27. Capasso, A.; Guerrini, R.; Balboni, G.; Sorrentino, L.; Temussi, P. A.; Lazarus, L. H.; Bryant, S. D.; Salvadori, S. Dmt-Tic-OH, a highly selective and potent δ opioidmimetic receptor antagonist after systemic administration in the mouse. Life Sci. 1996, 59, PL93-98.
28. Marsden, B. J.; Nguyen, T. M.-D.; Schiller, P. W. Spontaneous degradation via diketopiperazine formation of peptides containing a tetrahydroiosquinoline-3-carboxyIic acid residue in the 2-position of the peptide sequence. Int. J. Pept. Protein Res. 1993, 41, 313-316.
29. (a) Mazur, R. H.; Schlatter, J. M. A novel peptide cleavage reaction. J. Org. Chem. 1963, 28, 1025-1029.
30. (b) Wagner, F. W.; Kapleau, B. R.; Shepherd, S. L. Amino acid composition and sequence of urinary peptides containing hydroxyproline. Biochem. Med. 1975, 13, 343-352.
31. Capasso, S.; Sica, F.; Mazzarella, L.; Balboni, G.; Guerrini, R.; Salvadori, S. Acid catalysis in the formation of dioxopiperazines from peptides containing tetrahydroisoquinoline-3-carboxylic acid at position 2. Int. J. Pept. Protein Res. 1995, 45, 567-573.
32. (a) Prasad, C.; Peterkofsky, A. Demonstration of pyroglutamylpeptidase and amides activities toward thyrotropin-releasing hormone in hamster hypothalamus extracts. J. Biol. Chem. 1976, 251, 3229-3234.
33. (b) Bhargava, H. N. The effects of thyrotropin releasing hormone and histidyl-proline diketopiperazine on delta-9-tetrahydrocannabinol-induced hypothermia. Life Sci. 1980, 26, 845-850.
34. van der Greef, J.; Tas, A. C.; Nijssen, L. M.; Jetten, J. Identification and quantification of diketopiperazines by liquid chromatography-mass spectrometry, using a moving belt interface. J. Chromatogr. 1987, 394, 77-88.
35. (a) Sakurada, S.; Sakurada, T.; Jin, H.; Sato, T.; Kisara, K.; Sasaki, Y.; Suzuki, K. Antinociceptive activities of synthetic dipeptides in mice. J. Pharm. Pharmacol. 1982, 34, 750-751.
36. (b) Walter, R.; Ritzmann, R. F.; Bhargava, H. N.; Flexner, L. B. Prolyl-leucyl-glycinamide, cyclo(leucylglycine), and derivatives block development of physical dependence on morphine in mice. Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 518-520.
37. Balboni, G.; Guerrini, R.; Salvadori, S.; Tomatis, R.; Bryant, S. D.; Bianchi, C.; Attila, M.; Lazarus, L. H. Opioid diketopiperazines: Synthesis and activity of a unique class of δ opioid antagonists. Biol. Chem. Hoppe Seyler 1997, 375, 19-29.
38. Bryant, S. D.; Balboni, G.; Guerrini, R.; Salvadori, S.; Tomatis, R.; Lazarus, L. H. Opioid diketopiperazines: Refinement of the δ opioid antagonist pharmacophore. Biol. Chem. Hoppe Seyler 1997, 378, 107-114.
39. 4]deltorphin C analogues: novel probes for the δ-opioid receptor. Eur. J. Pharmacol. 1993, 230, 357-361.
40. Mosberg, H. I.; Heyl, D. L.; Haaseth, R. C.; Omnass, J. R.; Medzihradsky, F.; Smith, C. B. Cyclic dermorphin-like tetrapeptides with δ-opioid receptor selectivity. 3. Effect of residue 3 modification on in vitro opioid activity. Mol. Pharmacol. 1990, 38, 924-928.
41. 1 replacements in the cyclic δ receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13) J. Med. Chem. 1994, 37, 4371-4383.
42. 3 replacements in the cyclic δ receptor selective tetrapeptide Tyrc[D-Cys-Phe-D-Pen]OH (JOM-13). J. Med. Chem. 1994, 37, 4384-4391.
43. 5]enkephalin with δ opioid receptor selectivity. J. Med. Chem. 1992, 35, 2384-2391.
44. Shaw, J. S.; Miller, L.; Turnbull, M. J.; Gormally, J. J.; Morley, J. S. Selective antagonist at the opiate delta-receptor. Life Sci. 1982, 31, 1259-1262.
45. 10]dynorphin A-(1-11) are highly selective for κ-opioid receptors. J. Med. Chem. 1992, 35, 4638-4639.
46. 5]enkephalin. Int. J. Pept. Protein Res. 1990, 35, 452-459.
47. (a) Tonelli, A. E. The effects of isolated N-methylated residues on the conformational characteristics of polypeptides. Biopolymers 1976, 15, 1615-1622.
48. (b) Ogawa, H.; Burke, G. T.; Chanley, J. D.; Katsoyannis, P. G. Effect of N-methylation of selected peptide bonds on the biological activity of insulin. Int. J. Pept. Protein Res. 1987, 30, 460-473.
49. Bello, J. Helix formation in methylated copolymers of lysine and alanine. Biopolymers 1992, 32, 491-496.
50. Vitoux, B.; Aubry, A.; Chung, M. T.; Marraud, M. N-Methyl peptides. VII. Conformational perturbations by N-methylation of model peptides. Int. J. Pept. Protein Res. 1986, 27, 617-632.
51. (a) Turk, J.; Needleman, P.; Marshall, G. R. Analogues of bradykinin with restricted conformational freedom. J. Med. Chem. 1975, 78, 1139-1142.
52. (b) Turk, J.; Needleman, P.; Marshall, G. R. Analogues of angiotensin II with restricted conformational freedom, including a new antagonist. Mol. Pharmacol. 1976, 12, 217-224.
53. (c) Dive, V.; Yiotakis, A.; Roumestand, C.; Gilquin, B.; Labadie, J.; Toma, F. Peptide inhibitors of E. collagenolyticium bacterial collagenase-Effect of N-methylation consequences on biological activity and conformational properties. Int. J. Pept. Protein Res. 1992, 39, 506-515.
54. Benedetti, E.; Marsh, R. E.; Goodman, M. Conformational studies on peptides. X-Ray structure determinations of six N-methylated cyclic dipeptides derived from alanine, valine, and phenylalanine. J. Am. Chem. Soc. 1976, 98, 6676-6684.
55. 3 deltorphin analogues: Enhanced selectivity of halogenated derivatives for δ opioid receptor sites. J. Med. Chem. 1992, 35, 4651-4657.
56. 3-Substituted analogues of deltorphin C. Spatial conformation and topography of the aromatic ring in peptide recognition by δ opioid receptors. J. Med. Chem. 1993, 36, 3748-3756.
57. 5]-enkephalin. J. Med. Chem. 1991, 34, 1823-1830.
58. (b) He, Y.-B.; Huang, Z.; Raynor, K.; Reisine, T.; Goodman, M. Syntheses and conformations of somatostatin-related cyclic hexapeptides incorporating specific α- and β-methylated residues. J. Am. Chem. Soc. 1993, 115, 8066-8072.
59. 2 with replacement of Phe by βMePhe. In Peptides 1994; Maia, H. L. S., Ed.; ESCOM: Leiden, 1995; pp 335-336.
60. ω-Alkyldiamino acids: Chemistry and properties. In Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins; Weinstein, B., Ed.; Marcel Dekker: New York, 1978; pp 163-211.
61. (a) Tang, Y.; Chen, K.-X.; Jiang, H.-L.; Wang, Z.-X.; Ji, R.-Y.; Chi, Z.-Q. Molecular modeling of μ opioid receptor and its interaction with ohmefentanyl. Acta Pharmacol. Sinica 1996, 17, 156-160.
62. (b) Alkorta, I.; Loew, G. H. A 3D model of the δ opioid receptor and ligand-receptor complexes. Protein Eng. 1996, 9, 573-583.
63. (a) Befort, K.; Tabbara, L.; Kling, D.; Maigret, B.; Kieffer, B. Role of aromatic transmembrane residues of the δ-opioid receptor in ligand recognition. J. Biol. Chem. 1996, 277, 10161-10168.
64. (b) Valiquette, M.; Vu, H. K.; Yue, S. Y.; Wahlestedt, C.; Walker, P. Involvement of Trp-284, Val-296, and Val-297 of the human δ-opioid receptor in binding of δ-selective ligands. J. Biol. Chem. 1996, 277, 18789-18796.
65. Pepin, M.-C.; Yue, S. Y.; Roberts, E.; Wahlestedt, C.; Walker, P. Novel "restoration of function" mutagenesis strategy to identify amino acids of the δ-opioid receptor involved in Ligand binding. J. Biol. Chem. 1997, 272, 9260-9267.
66. Hruby, V. J.; Gehrig, C. A. Recent developments in the design of receptor specific opioid peptides. (1989) Med. Res. Rev. 1989, 9, 343-401.
67. Brandt, W.; Barth, A.; Höltje, H.-D. A new consistent model explaining structure (conformation)-activity relationships of opiates with μ-selectivity. Drug Des. Discovery 1993, 10, 257-283.
68. (a) Rónai, A. Z.; Botyánski, J.; Magyar, A.; Borsodi, A.; Benyhe, S.; Medzihradszky, K. Novel, δ-opioid receptor-selective peptide antagonists: Demonstration of a possible opioid interaction in the absence of a protonated nitrogen and attempts to locate the protonated nitrogen site. Arch. Int. Pharmacodyn. 1993, 323, 114-125.
69. 1 analogues. Arch. Int. Pharmocodyn. 1995, 330, 361-369.
70. Misicka, A.; Lipkowski, A. W.; Slaninova, J.; Davis, P.; Yamamura, H. I.; Porreca, F.; Hruby, V. J. The synthesis and opioid receptor binding affinities of analogues of dermorphin and its N-terminal tetrapeptide fragment with dibasic acids in position 2. Life Sci. 1995, 57, 1633-1640.
71. (a) Benedetti, E.; Corradini, P.; Pedone, C. Crystal and molecular structure of L-cis-3,6-dimethyl-2,5-piperazinedione (L-alanyl-L-alanyl-2,5-diketopiperazine). Biopolymers 1969, 7, 751-764.
72. (b) Benedetti, E.; Corradini, P.; Pedone, C. The crystal and molecular structure of trans-3,6-dimethyl-2,5-piperazinedione (L-alanyl-L-alanyl-2,5-diketopiperazine). J. Phys. Chem. 1969, 73, 2891-2895.
73. (a) Kong, H.; Raynor, K.; Yasuda, K.; Moe, S. T.; Portoghese, P. S.; Bell, G. I.; Reisine, T. A single residue, aspartic acid 95, in the δ opioid receptor specifies selective high affinity agonist binding. J. Biol. Chem. 1993, 268, 23055-23058.
74. (b) Claude, P. A.; Wotta, D. R.; Zhang, X. H.; Prather, P. L.; McGinn, T. M.; Erickson, L. J.; Loh, H. H.; Law, P. Y. Mutation of a conserved serine in TM4 of opioid receptors confers full agonistic properties to classical antagonists. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 5715-5719.
75. Moran, S.; Ren, R. X.-F.; Rumney, IV, S.; Kool, E. T. Difluorotoluene, a nonpolar isostere for thymine, codes specifically and efficiently for adenine in DNA replication. J. Am. Chem. Soc. 1997, 119, 2056-2057.
76. Vaughn, L. K.; Wire, W. S.; Davis, P.; Shimohigashi, Y.; Toth, G., Knapp, R. J.; Hruby, V. J.; Burks, T. F.; Yamamura, H. I. Differentiation between rat brain and mouse vas deferens δ opioid receptors. Eur. J. Pharmacol. 1990, 177, 99-101.
77. (a) Gacel, G. A.; Fellion, E., Baamonde, A.; Dauge, V.; Roques, B. P. Synthesis, biochemical and pharmacological properties of BUBUC, a highly selective and systemically active agonist for in vivo studies of δ-opioid receptors. Peptides 1990, 11, 983-988.
78. 5]enkephalin. J. Med. Chem. 1991, 34, 1923-1830.
79. (c) Schiller, P. W.; Weltrowska, G.; Nguyen, T. M.-D.; Lemieux, C.; Chung, N. N.; Marsden, B. J.; Wilkes, B. C. Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: Effects on receptor selectivity and stereospecificity. J. Med. Chem. 1991, 34, 3125-3132.
80. (d) Schiller, P. W.; Weltrowska, G.; Nguyen, T. M.-D.; Wilkes, B. C.; Chung, N. N.; Lemieux, C. Conformationally restricted deltorphin analogues. J. Med. Chem. 1992, 35, 3956-3961.
81. (e) Misicka, A.; Lipkowski, A. W.; Horvath, R.; Davis, P.; Yamamura, H. I.; Porreca, F.; Hruby, V. J. Design of cyclic deltorphins and dermenkephalins with a disulfide bridge leads to analogues with high selectivity for δ-opioid receptors. J. Med. Chem. 1994, 37, 141-145.
82. (a) Belkowski, S. M.; Zhu, J.; Liu-Chen, L.-Y.; Eisenstein, T. K.; Adler, M. W.; Rogers, M. W. Sequence of κ-opioid receptor cDNA in the R1.1 thymoma cell line. J. Neuroimmunol. 1995, 62, 113-117.
83. (b) Zimprich, A.; Simon, T.; Höllt, V. Cloning and expression of an isoform of the rat μ opioid receptor (rMOR1B) which differs in agonist induced desensitization from rMOR1. FEBS Lett. 1995, 359, 142-146.
84. (c) Mayer, P.; Schulzeck, S.: Kraus, J.; Zimprich, A.; Höllt, V. Promoter region and alternatively spliced exons of the rat μ-opioid receptor gene. J. Neurochem. 1996, 66, 2272-2278.
85. Yakovlev, A. G.; Krueger, K. E.; Faden, A. I. Structure and expression of a rat κ opioid receptor gene. J. Biol. Chem. 1995, 270, 6421-6424.
86. (a) Jian, Q.; Takemori, A.; Sultana, M.; Portoghese, P.; Bowen, W.; Mosberg, H. I.; Porreca, F. Differential antagonism of opioid delta antinociception by [D-Ala,Leu,Cys]enkephalin and naltrindole 5′-isothiocyanate: evidence for delta receptor subtypes. J. Pharmacol. Exp. Ther. 1991, 257, 1069-1075.
87. 4]-substituted derivatives: Further evidence of opioid delta receptor multiplicity. J. Pharmacol. Exp. Ther. 1993, 265, 896-902.
88. 3]DPDPE: A new enkephalin analog with a unique opioid receptor activity profile. Further evidence of δ-opioid receptor multiplicity. J. Med. Chem. 1994, 37, 1572-1577.
89. 4]deltorphin with δ-o-pioid receptor subtypes in vivo. Eur. J. Pharmacol. 1994, 252, 133-137.
90. Borch, R. F.; Hassid, A. I. A new method for the methylation of amines. J. Org. Chem., 1972, 37, 1673-1674.
91. Abrash, H. I.; Niemann, C. Steric hindrance in α-chymotrypsincatalyzed reactions. Biochemistry 1963, 2, 947-952.
92. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
93. Kosterlitz, H. W.; Watt, A. J. Kinetic parameters of narcotic agonists and antagonists, with particular reference to N-allylnoroxymorphone (naloxone). Br. J. Pharmacol. Chemother. 1968, 33, 266-276.
94. Arunlakshana, O.; Schild, H. O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. 1959, 14, 48-58.
95. Tallarida, R. J.; Murray, R. B. Manual of Pharmacology Calculation with Computer Programs; Springer-Verlag: Berlin, 1986.